Position in LIMN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$60,200
New position
Shares Held
7,000
first reported quarter
Ownership
0.521%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cygnus Capital Advisors, LLC holds $1,193,824 across 18 Biotechnology names. LIMN ranks #8 (5.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZYME |
Zymeworks Inc.
|
8,197 | $205,252 | |
| 2 | SION |
Sionna Therapeutics, Inc.
|
3,800 | $152,342 | |
| 3 | IMNM |
Immunome Inc.
|
6,880 | $150,465 | |
| 4 | ANNX |
Annexon, Inc.
|
22,200 | $122,988 | |
| 5 | EWTX |
Edgewise Therapeutics, Inc.
|
3,427 | $107,950 | |
| 6 | CMPX |
Compass Therapeutics, Inc.
|
18,000 | $95,220 | |
| 7 | RANI |
Rani Therapeutics Holdings, Inc.
|
115,649 | $85,002 | |
| 8 | LIMN |
Liminatus Pharma, Inc.
This page
|
7,000 | $60,200 |
All Filings in LIMN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $60,200 | 350,000 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||